Journal: International journal of cancer

Article Title: Serum haptoglobin as a novel molecular biomarker predicting colorectal cancer hepatic metastasis.

doi: 10.1002/ijc.29993

Figure Lengend Snippet: Figure 1. Elevated HP levels in colorectal cancer patients. (a) Serum levels of HP in healthy controls and colorectal cancer patients. (b) The serum levels of HP in healthy controls (n 5 152) and colorectal cancer patients [M0, M1(S), and M1(H), n 5 250] were measured by ELISA. (c) Kaplan–Meier survival curve showed correlation between HP serum level and overall survival. (*, p<0.05) [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

Article Snippet: Measurement of HP level in human blood samples A commercially available ELISA kit Human Haptoglobin ELISA Kit(Assaypro EH1003-1)was used to measure HP level.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Journal of sports sciences

Article Title: A comparison of haemolytic responses in fore-foot and rear-foot distance runners.

doi: 10.1080/02640414.2015.1119300

Figure Lengend Snippet: Figure 1. Mean (±SEM) serum haptoglobin (Hp) recorded pre- and post-interval running trial, and the pre- to post-change values, for the fore-foot (FF) and rear- foot (RF) running groups. ǂSignificantly different to baseline (P ≤0.05).

Article Snippet: Serum haptoglobin levels were determined using a Quantikine® enzyme-linked immunosorbent assay (ELISA) kit for human haptoglobin (R&D Systems, Minneapolis, MN, USA).

Techniques:

Journal: Frontiers in Oncology

Article Title: Proteomic Alterations in Multiple Myeloma: A Comprehensive Study Using Bone Marrow Interstitial Fluid and Serum Samples

doi: 10.3389/fonc.2020.566804

Figure Lengend Snippet: Validation experiments for some of the candidate proteins using ELISA. (A) Concentration ranges of serum albumin in healthy controls (42.80 mg/ml ± 10.13 mg/ml), MM patients (26.45 mg/ml ± 8.14 mg/ml). (B) Concentration ranges of serum apolipoprotein a1 in healthy controls (152.05 mg/dl ± 30.61 mg/dl), MM patients (105.97 mg/dl ± 38.80 mg/dl). (C) Concentration ranges of serum kininogen 1 in healthy controls (139.38 µg/dl ± 28.98 µg/dl), MM patients (173.95 µg/dl ± 26.60 µg/dl), (D) Concentration ranges of serum haptoglobin in healthy controls (110.86 mg/dl ± 30.99 mg/dl), MM patients (145.28 mg/dl ± 45.03 mg/dl). (E) Concentration ranges of serum transferrin in healthy controls (2.64 g/L ± 0.69 g/L), MM patients (1.76 g/L ± 0.48 g/L). Healthy control serum samples (n = 36), MM patients serum samples (n = 36). ****p-value ≤ 0.0001, ***p-value ≤ 0.001.

Article Snippet: We validated a panel of five proteins with the Human Haptoglobin Quantikine ELISA kit (catalog #DHAPG0; R&D Systems, Inc., Minneapolis, USA), Human Kininogen DuoSet ELISA kit (catalog #DY1569-05; R&D Systems, Inc., Minneapolis, USA), Human Apolipoprotein A-I Quantikine ELISA Kit (catalog #DAPA10; R&D Systems, Inc., Minneapolis, USA), Human sTfR Quantikine IVD ELISA Kit (1 Kit) (catalog #DTFR1; R&D Systems, Inc., Minneapolis, USA), Human Serum Albumin DuoSet ELISA, 15 Plate (1 KIT) (catalog #DY1455; R&D Systems, Inc., Minneapolis, USA).

Techniques: Biomarker Discovery, Enzyme-linked Immunosorbent Assay, Concentration Assay, Control

Journal: MedComm

Article Title: Robust Diagnostic and Therapeutic Biomarkers for Tuberculosis Identified Through Multi‐Omics and Mendelian Randomization Analysis

doi: 10.1002/mco2.70559

Figure Lengend Snippet: Multi‐omics combined with Mendelian randomization for robust biomarker discovery in tuberculosis . (A) Volcano plot of differentially expressed genes (DEGs) between TB patients ( n = 46) and healthy controls ( n = 37) from GEO dataset GSE28623 . A total of 290 DEGs were identified (177 upregulated and 113 downregulated) under the criteria |log2FC| > 1.2 or < 0.83 and adjusted p < 0.05. (B) Integration pipeline: By combining genes related to PC(18:2/18:2) and PC(14:0/20:4) (PC‐gene), MR results for 4907 proteins (MR‐protein), proteomic differential expression results (Proteomics), and GEO transcriptomic data (GEO), we identified haptoglobin (HP) as a target biomarker. (C) Violin plot showing differential expression of HP between TB patients and healthy controls in GSE28623 . (D) Violin plot showing differential expression of HP between TB patients ( n = 8) and healthy controls ( n = 18) in GSE34608 . (E) ROC curve assessing the diagnostic performance of HP expression for discriminating TB patients from healthy controls in the GSE34608 dataset. AUC = 0.965 (95% CI: 0.875–1.000). (F) Confusion matrix for HP‐based classification of TB patients versus healthy controls in the GSE34608 dataset (“Yes” represents tuberculosis patients and “No” represents healthy people). (G) Violin plot showing differential expression of HP between TB patients ( n = 8) and healthy controls ( n = 8) in ELISA. (H) ROC curve assessing the diagnostic performance of HP expression for discriminating TB patients from healthy controls in the ELISA. AUC = 0.969 (95% CI: 0.903–1.000). (I) Confusion matrix for HP‐based classification of TB patients versus healthy controls in the ELISA (“Yes” represents tuberculosis patients and “No” represents healthy people).

Article Snippet: Plasma HP concentrations were measured using the QuicKey Pro Human HP (Haptoglobin) ELISA Kit (Catalog No. E‐OSEL‐H0044; Elabscience) according to the manufacturer's instructions.

Techniques: Biomarker Discovery, Quantitative Proteomics, Diagnostic Assay, Expressing, Enzyme-linked Immunosorbent Assay